Ose Immunotherapeutics Sa

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

OSE Immunotherapeutics Evolves its Leadership Team

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

OSE Immunotherapeutics Announces its 2026 Financial Calendar